Quadrant Capital Group’s CureVac CVAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-39,311
| Closed | -$178K | – | 2736 |
|
|
2025
Q4 | $178K | Sell |
39,311
-1,543
| -4% | -$7.91K | 0.01% | 1318 |
|
|
2025
Q3 | $220K | Buy |
40,854
+1,543
| +4% | +$8.35K | 0.01% | 1245 |
|
|
2025
Q2 | $213K | Sell |
39,311
-5,685
| -13% | -$22.5K | 0.01% | 1268 |
|
|
2025
Q1 | $125K | Sell |
44,996
-5,020
| -10% | -$17.5K | ﹤0.01% | 1474 |
|
|
2024
Q4 | $171K | Buy |
50,016
+19,098
| +62% | +$55.1K | 0.01% | 775 |
|
|
2024
Q3 | $90.9K | Sell |
30,918
-3,160
| -9% | -$10.4K | 0.01% | 1124 |
|
|
2024
Q2 | $116K | Buy |
34,078
+15,291
| +81% | +$50K | 0.01% | 928 |
|
|
2024
Q1 | $56.9K | Buy |
18,787
+16,879
| +885% | +$59.3K | ﹤0.01% | 1318 |
|
|
2023
Q4 | $8.03K | Buy |
1,908
+1,134
| +147% | +$6.15K | ﹤0.01% | 2141 |
|
|
2023
Q3 | $5.29K | Sell |
774
-801
| -51% | -$7.07K | ﹤0.01% | 2158 |
|
|
2023
Q2 | $16.4K | Buy |
1,575
+805
| +105% | +$7.2K | ﹤0.01% | 1812 |
|
|
2023
Q1 | $5.37K | Buy |
770
+358
| +87% | +$3.12K | ﹤0.01% | 2215 |
|
|
2022
Q4 | $2.48K | Sell |
412
-978
| -70% | -$7.22K | ﹤0.01% | 2356 |
|
|
2022
Q3 | $11K | Sell |
1,390
-2,379
| -63% | -$27.7K | ﹤0.01% | 1837 |
|
|
2022
Q2 | $51K | Buy |
3,769
+838
| +29% | +$13.9K | 0.01% | 864 |
|
|
2022
Q1 | $57K | Buy |
2,931
+1,573
| +116% | +$31.4K | 0.01% | 865 |
|
|
2021
Q4 | $47K | Buy |
1,358
+1,349
| +14,989% | +$54.3K | 0.01% | 949 |
|
|
2021
Q3 | $0 | Buy |
+9
| New | +$542 | ﹤0.01% | 2528 |
|
Quadrant Capital Group's CVAC Position: Q1 2026 in Review
Quadrant Capital Group sold out of CureVac (CVAC) in Q1 2026, closing a stake of 39,311 shares — an estimated $178K sold.
Quadrant Capital Group first reported a position in CVAC in Q3 2021 and held it in 18 quarters. The position peaked at $220K in Q3 2025. 0 funds tracked by Wall St. Rank hold CVAC as of Q1 2026.
- Quadrant Capital Group reported no remaining CureVac position as of Q1 2026 after selling out during the quarter.
- Quadrant Capital Group sold 39,311 CureVac shares in Q1 2026, an estimated $178K.
- Quadrant Capital Group first reported a position in CureVac in Q3 2021 and held it in 18 quarters.
- Quadrant Capital Group's CureVac position peaked at $220K in Q3 2025.
- 0 funds tracked by Wall St. Rank held CureVac as of Q1 2026.
Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.